Pault Quinlan News Today

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on CBAY. Piper Sandler reaffirmed a neutral rating and issued a $32.50 price target (down from $33.00) on shares […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday, Briefing.com reports. Several other equities analysts have also issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of […]

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.72 and last traded at $24.89, with a volume of 549844 shares traded. The stock had previously closed at $24.00. Analyst Ratings Changes CBAY has been the subject […]

Emerald Mutual Fund Advisers Trust acquired a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 809,738 shares of the biopharmaceutical company’s stock, valued at approximately $12,073,000. Emerald Mutual Fund Advisers […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $21.98, for a total transaction of $109,900.00. The transaction was disclosed in a legal filing with the SEC, […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $17.38, for a total transaction of $86,900.00. The transaction was disclosed in a filing with the SEC, which […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $17.38, for a total value of $86,900.00. The transaction was disclosed in a legal filing with the Securities & […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective hoisted by Raymond James from $33.00 to $34.00 in a report issued on Wednesday morning, Benzinga reports. Raymond James currently has a strong-buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on the stock. B. Riley lifted their […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its target price hoisted by Piper Sandler from $19.00 to $33.00 in a research note released on Monday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on CBAY. Cantor Fitzgerald reiterated an overweight rating and […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect CymaBay Therapeutics to post earnings of ($0.30) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. CymaBay Therapeutics (NASDAQ:CBAY – […]